A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer
Interventions: DRUG: Camrelizumab Plus Chemotherapy|DRUG: placebo+chemotherapy
Sponsor: Jiangsu HengRui Medicine Co., Ltd.